BMY Oct 2024 41.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:53PM EDT. Market open.
| Previous Close | 2.4800 |
| Open | 2.7000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 41.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 2.4800 - 2.7200 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 364 |
Business WireBristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., May 29, 2024--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line...
ACCESSWIREASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 /Originally published on Bristol Myers Squibb News & Perspectives Globally, communities are struggling to support growing healthcare needs. This is especially true in regions with limited financial resources, ...
Business WireBristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
PRINCETON, N.J., May 23, 2024--Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications....
© 2024 Yahoo. All rights reserved.